http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020111379-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e8d2afa63dbd8bbb90545722d3f54c1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2015-8572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-912 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-206 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4739 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-11022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 2018-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71bffc17cdb4341dccd6ae3711b08d34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93cf5db09f695062abe4dca56c5206c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfe3de2355639985957ca9248de6cb8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_267b3cf53ebb35b85c55d79aa3a3d277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e2be95233c86c972c95b3290230cbe1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa1a8ae6484e141cef2491ad7b5a793c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b93b4751a3b0c08fa4dea0e8c6358d64 |
| publicationDate | 2020-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020111379-A1 |
| titleOfInvention | A method for screening a therapeutic agent for cancer using binding inhibitor of cyclin-dependent kinase 1 (cdk1)-cyclin b1 and retinoic acid receptor responder 1 (rarres1) gene knockout animal model |
| abstract | The present invention relates to a method of screening for a cancer therapeutic agent using Cyclin B1, Cyclin-dependent kinase 1 (CDK1), and retinoic acid receptor responder 1 (RARRES1), and a composition for diagnosing cancer or predicting a prognosis using the same. As a result of having conducted intensive studies to discover molecular mechanisms for diagnosing cancer and predicting a prognosis, the inventors of the present invention confirmed that in cancer-derived samples, according to the degree of mutual binding between RARRES1 and CDK1 or Cyclin B1, the mitosis of cancer cells was arrested, the formation of CDK1-Cyclin B1 complexes was suppressed, and the degradation of these proteins was promoted, and thus RARRES1 was a crucial factor in the diagnosis of cancer, prognosis prediction, and the treatment of cancer. In addition, through these findings, it is anticipated that RARRES1 may be widely used in screening for a cancer therapeutic agent exhibiting a decrease in the degree of binding between CDK1 and Cyclin B1, an increase in the degree of binding between the RARRES1 gene and CDK1 or Cyclin B1, and a decrease in an amount or activity of the CDK1 protein or the Cyclin B1 protein, and in the development of drugs. In addition, the present invention relates to a targeting vector including a portion of the Rarres1 gene and sequences used in producing a conditional knockout animal model, an animal cell for producing a tumorigenic animal model, which is produced using the targeting vector, a tumorigenic Rarres1-/- animal model produced using the animal cell, a method of producing the animal model, and a method of screening for a cancer therapeutic agent by using the method. Thus, as a result of having conducted intensive studies to discover molecular mechanisms for diagnosing cancer and predicting a prognosis, the inventors of the present invention confirmed that a Rarres1-/- animal model was prone to spontaneous tumors and exhibited increased phosphorylation of CDK1 and Cyclin B1 and a high activity of a CDK1-Cyclin B1 complex, and thus it was confirmed that the tumor cell cycle progression was unusually rapid due to a decrease in protein degradation ability. In particular, it was confirmed that stem cell proliferation was increased, and chromosomes were unstable upon induction of mitotic defects and mitosis, from which it was confirmed that RARRES1 is a crucial factor in diagnosing cancer, predicting a prognosis, and treating cancer. Moreover, it is anticipated that the Rarres1-/- animal model can be variously used for screening for a cancer therapeutic agent and developing a drug, through the relationship between RARRES1 and a CDK1-Cyclin B1 complex, the quantitative regulation of the CDK1 and Cyclin B proteins, and an increase in stem cell proliferative ability. |
| priorityDate | 2018-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 651.